Oura Ring now links sleep changes to Resmed sleep resources
Oura and Resmed have partnered to provide Oura Ring members in the U.S. with expanded access to sleep health education and care pathways. Oura Ring Gen3 and Ring 4 users can now access Resmed's educational tools, sleep assessments, and connect with independent healthcare providers to address sleep concerns, especially in light of the high rate of undiagnosed obstructive sleep apnea. This collaboration aims to help individuals better understand their sleep patterns and take informed action on potential issues.
Artivion Q1 2026 Earnings: Revenue Matches Estimates, EPS Misses by 35% - News and Statistics
Artivion's Q1 2026 earnings saw revenue of $116.3 million, matching analyst estimates, but adjusted EPS missed expectations by 35.1% at $0.08 versus $0.12. The company attributed the shortfall to weak stent graft sales and delays in AMDS starter set sales due to hospital procurement issues, leading to a downward revision in full-year revenue and EBITDA guidance. Analysts questioned management on the conservatism of the revised guidance and the impact of future PMA approval for AMDS.
Laura Friedman from California’s 30th District makes transactions in Hologic, Inc.
Laura Friedman, representative for California’s 30th congressional district, recently executed two transactions involving Hologic, Inc. She exchanged common stock for non-tradable contingent value rights and partially sold common stock due to the company's privatization. Both transactions, valued between $1,001 and $15,000, were processed via Fidelity Brokerage Services, LLC, and reported on May 3, 2026.
VolitionRX Ltd (VNRX) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic Partnerships Propel Growth
VolitionRX Ltd (VNRX) reported a substantial 300% year-on-year revenue increase in Q1 2026, reaching approximately $1 million, largely due to deferred revenue from a new QVET agreement. Despite rising operating expenses and increased cash usage, the company made significant progress in automating its NuQ Vet Cancer Test, expanding its global collaborator network, and advancing discussions for licensing its intellectual property. VolitionRX also achieved a technical milestone in sepsis testing and is pursuing commercialization through strategic partnerships, though revenue guidance remains unpredictable due to its early stage of commercialization.
Veracyte Gains Medicare Coverage for Muscle-Invasive Bladder Cancer Recurrence Monitoring Test
Veracyte's TrueMRD Monitoring Test has received Medicare coverage for recurrence monitoring in patients with muscle-invasive bladder cancer (MIBC) following definitive treatment. This makes it Veracyte’s first molecular residual disease (MRD) commercial offering and the first commercially available whole-genome MRD test on the market. The test, which launches June 1, 2026, aims to improve early detection of recurrence and inform treatment decisions, especially as MIBC patients have a high recurrence rate within two years.
Laura Friedman from California’s 30th District makes transactions in Hologic, Inc. By Investing.com
Laura Friedman, a representative from California’s 30th congressional district, recently reported two transactions involving Hologic, Inc. These transactions, which occurred on April 8, 2026, and were reported on May 3, 2026, included an exchange of common stock for a contingent value right and a partial sale of common stock due to privatization. Both transactions, valued between $1,001 and $15,000, were executed via Fidelity Brokerage Services, LLC, and Friedman still retains a non-tradable contingent value right in the now-private company.
Laura Friedman from California’s 30th District makes transactions in Hologic, Inc.
Laura Friedman, a representative from California’s 30th congressional district, reported two recent transactions in Hologic, Inc. (NASDAQ:HOLX) through Fidelity Brokerage Services, LLC. The transactions, which occurred on April 8, 2026, involved an exchange of common stock for a non-tradable contingent value right and a partial sale of common stock due to the company's privatization, both valued within the $1,001 to $15,000 range. Despite the sale, Friedman still holds a non-tradable CVR in the now-private Hologic, Inc., a company specializing in diagnostic products and medical imaging systems.
CapsoVision (Nasdaq:CV) - Stock Analysis
CapsoVision (Nasdaq:CV) is a medical technology company specializing in endoscopic video imaging devices for gastrointestinal imaging, currently valued at US$322.5m. The company faces significant financial risks, including less than a year of cash runway and continued unprofitability, although revenue is forecast to grow by 27.2% annually. Recent developments include an FDA 510(k) submission for an AI-assisted reading module and a Breakthrough Device Designation application for pancreatic cancer screening.
Why This Fund Made a $35 Million Bet on IHS Towers During a Major Shakeup
PSquared Asset Management invested $35.75 million in IHS Holding Limited (NYSE:IHS) during the first quarter of 2026, acquiring over 4.3 million shares. This new position represents 12.44% of PSquared's reportable assets under management and suggests a high-conviction bet on IHS Towers' financial durability and potential upside from strategic transactions. The investment comes as IHS Towers recorded strong first-quarter financial results and pursues the sale of Latin American operations and a proposed acquisition by MTN Group.
Rising revenue but cash risk at VolitionRx (NYSE: VNRX) in Q1 2026
VolitionRx (NYSE: VNRX) reported Q1 2026 revenues of $985,076 and a net loss of $6.7 million, with an operating cash outflow of $5.3 million, leaving $3.1 million in cash. The company faces "substantial doubt" about its ability to continue as a going concern due to recurring losses, negative cash flows, and significant liabilities. Funding relies on equity raises and convertible notes, with future disclosures on cash generation and commercial traction being critical for its financial sustainability.
Hologic stock (US4364401012): Analyst hold consensus with limited upside
Hologic (HOLX) has received a consensus "hold" rating from Wall Street analysts, with an average price target of $79.09, suggesting limited upside from its recent trading price of around $76.07. The company specializes in women's health diagnostics and imaging, with key products in breast cancer screening and HPV testing. Despite facing competition, Hologic maintains a strong position in the US market, driven by innovation in precision medicine and increasing demand for early detection technologies.
Hologic, Inc. (HOLX) is a trending stock: Facts to know before betting on it
This article analyzes why Hologic, Inc. (HOLX) is currently a trending stock and what investors should consider before making an investment decision. It likely covers key financial metrics, recent performance, and other relevant factors to help readers understand the company's position.
Mental Health Technology Market Is Going to Boom | Talkspace, BetterHelp, Headspace, Calm
Coherent Market Insights has published a new study titled "Mental Health Technology Market 2026," which provides a detailed evaluation of this market. The report offers high-impact insights into regional and global market growth projections from 2026 to 2033, including market dynamics, value chain analysis, competitive landscape, and market segments. It aims to equip business leaders, investors, and industry participants with strategic tools for identifying growth avenues and optimizing market entry strategies.
Hologic, Inc. (HOLX) is a trending stock: Facts to know before betting on it
This article is a placeholder indicating that Hologic, Inc. (HOLX) is currently a trending stock. It suggests that potential investors should gather information before making investment decisions regarding HOLX. However, the article provides no actual content or facts about the company or its stock performance.
Hologic stock (US4364401012): Blackstone and TPG acquisition nears completion
Blackstone and TPG Global are acquiring Hologic, a leading women's health diagnostics company, in an all-cash deal expected to close around April 7, 2026. This acquisition signifies the strategic value of women's health solutions and diagnostics in the healthcare market and transitions Hologic to private ownership. The move is anticipated to boost investment in research, development, and expansion for the company.
HCA Healthcare (BIT:1HCA) - Stock Analysis
HCA Healthcare (BIT:1HCA) is analyzed as trading below its estimated fair value with projected annual earnings growth of 4.04%. The company recently announced executive changes, quarterly dividends, and details regarding board refreshment, which was noted as insufficient by Simply Wall St's risk model. Recent analysis also highlighted HCA Healthcare's negative shareholder equity and a new minor risk related to share price stability.
Body Composition Analyzers Market is expected to Hit US$ 1.25 billion by 2033 | Major Companies - GE Healthcare Inc., Hologic Inc., Inbody Co. Ltd, Jawon Medical Co. Ltd
The global Body Composition Analyzers Market is projected to reach US$ 1.25 billion by 2033, growing at a CAGR of 6.8% from its 2025 valuation of US$ 0.75 billion. This growth is driven by increasing health awareness, rising obesity rates, and technological advancements, with significant industry developments noted in the US and Japan. Key players in this market include GE Healthcare Inc., Hologic Inc., and Inbody Co. Ltd, focusing on devices that measure body fat, muscle mass, and bone density for various healthcare and fitness applications.
New Hampshire Justices Dissect Hologic’s Business Tax Method
The New Hampshire Supreme Court heard arguments regarding Hologic Inc.'s method of offsetting capital gains with capital losses from different subsidiaries for state business tax purposes. The state revenue department challenged a lower court ruling that favored Hologic, arguing that the company's method violated state reporting provisions. Chief Justice Gordon J. MacDonald questioned the state's interpretation in light of unitary business theory.
Hologic stock (US4364401012): Joins S&P SmallCap 600 ahead of May 14
Hologic, a medical technology company focused on women's health, is set to join the S&P SmallCap 600 index effective May 14, 2026. This inclusion is expected to increase the company's visibility and liquidity for US investors. Hologic's core business involves diagnostic, imaging, and surgical products, with a strong focus on breast health solutions and a significant market share in mammography.
New Hampshire Justices Dissect Hologic’s Business Tax Method
The New Hampshire Supreme Court is reviewing a tax dispute involving Hologic Inc. and the state’s revenue department. The case centers on whether Hologic can use capital losses from one subsidiary to offset capital gains from another for state business tax purposes. The high court questioned the state's solicitor general regarding the department's interpretation of tax provisions in relation to unitary business theory.
New Hampshire Justices Dissect Hologic’s Business Tax Method
The New Hampshire Supreme Court heard arguments regarding Hologic Inc.'s method of offsetting capital gains with capital losses from a subsidiary for state business tax purposes. The state revenue department is challenging a lower court's ruling that allowed Hologic's method. Chief Justice Gordon J. MacDonald questioned whether the department's interpretation aligned with unitary business theory.
New Hampshire Justices Dissect Hologic’s Business Tax Method
The New Hampshire Supreme Court heard arguments regarding Hologic Inc.'s method of offsetting capital gains with a subsidiary's capital losses for state business tax purposes. The state's Solicitor General appealed a lower court ruling that favored Hologic, arguing against the legality of the offsetting method under state combined reporting provisions. Chief Justice Gordon J. MacDonald questioned whether the state revenue department's interpretation aligned with the unitary business theory.
New Hampshire Justices Dissect Hologic’s Business Tax Method
The New Hampshire Supreme Court is reviewing a lower court's decision regarding Hologic Inc.'s method of offsetting capital gains with capital losses from its subsidiaries for state business tax purposes. Solicitor General Anthony J. Galdieri is arguing against the lower court's ruling, which stated that the state revenue department's denial of Hologic's method violated state reporting provisions. Chief Justice Gordon J. MacDonald is questioning whether the department's interpretation is consistent with unitary business theory.
Human Papillomavirus Testing Market Witnesses Asia-Pacific & North America Growth | Roche, Qiagen, Hologic
The global Human Papillomavirus (HPV) testing market is undergoing a significant transformation, moving from a supplementary diagnostic to a primary screening tool for cervical cancer prevention. Fact.MR projects the market to grow from USD 2.03 billion in 2026 to USD 3.96 billion by 2036, driven by government initiatives, technological advancements like PCR-based testing, and the potential of self-collection methods. While North America leads in demand, Asia-Pacific, particularly India and China, is emerging as the fastest-growing region due to expanding healthcare infrastructure and increased awareness.
OM1 Supports 650,000 Patient Real-World Regulatory Submission for FDA Approval of Hologic's Aptima HPV Assay
OM1 played a pivotal role in a massive 650,000-patient real-world evidence study that supported the FDA approval of Hologic's Aptima HPV Assay for primary cervical cancer screening. The study, which utilized OM1's AI-powered platform for data automation and rigorous validation, demonstrates the potential of real-world evidence in regulatory submissions and how automation can reduce constraints without compromising data quality. This landmark approval highlights the significant implementation of real-world evidence in the regulatory process for medical devices.
Primary Care Poc Diagnostics Market Is Going to Boom | Cepheid, Hologic
Coherent Market Insights has released a comprehensive report titled "Primary Care Poc Diagnostics Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast, 2026-2033." This study provides an in-depth analysis of market performance, competitive dynamics, regional performance, and long-term growth potential. It covers critical success factors, risk assessment, economic analysis, and anticipated return on investment, serving as a vital resource for various stakeholders in the market.
OM1 Supports 650,000 Patient Real-World Regulatory Submission for FDA Approval of Hologic's Aptima HPV Assay
OM1 played a crucial role in enabling a large-scale real-world evidence study for Hologic's Aptima HPV Assay, which recently received FDA approval for primary cervical cancer screening. The study involved over 650,000 patients and leveraged OM1's AI-powered platform for data automation, quality control, and extraction of key variables from unstructured clinical data, making the extensive regulatory submission feasible. This achievement highlights how AI-enabled evidence generation can meet FDA requirements, significantly overcoming the challenges of traditional manual data collection for large studies.
OM1 Supports 650,000 Patient Real-World Regulatory Submission for FDA Approval of Hologic's Aptima HPV Assay
OM1 supported Hologic's Aptima HPV Assay FDA approval with a landmark real-world evidence study involving 650,000 patients. The study leveraged OM1's AI platform for data automation, processing unstructured clinical notes and records to meet regulatory standards. This demonstrates the feasibility of using automation and real-world evidence for large-scale regulatory submissions, significantly reducing the manual effort traditionally required.
Hologic stock (US4364401012): Takeover deal and women’s health focus in focus
Hologic, a medical technology company focused on women's health, is set to be taken private by Blackstone and TPG in an $18.3 billion deal. This acquisition will reshape Hologic's capital structure and governance, impacting how US investors evaluate its risk-return profile. The company's core business revolves around diagnostics, surgery, and medical imaging for women's health conditions, benefiting from long-term trends in early detection and preventive care.
Hologic Nurse Advocate Program: Support for Heavy Periods & Fibroids
Hologic's Nurse Advocate Program, led by registered nurses Annie Yehudian and Jamie Hosman, provides support and education for women experiencing abnormal uterine bleeding (AUB) and fibroids. The program aims to empower women to understand their treatment options beyond hysterectomy, connecting them with specialists and advocating for open conversations about women's health issues. While not offering medical advice, the nurses help patients navigate their care journey and make informed decisions.
Hereditary Cancer Testing Market Will Generate Booming Growth
The global hereditary cancer testing market is experiencing significant growth, projected to reach US$14.59 billion by 2031 from US$5.05 billion in 2021. This expansion is driven by increasing cancer prevalence, advancements in next-generation sequencing, and a growing emphasis on personalized medicine and preventive oncology. Key industry players are focusing on innovation and strategic partnerships to meet the rising demand for early detection and risk assessment tools.
How many employees work at RxSight?
Revelio Labs reports that RxSight, Inc. currently has 439 employees, with a year-over-year growth rate of -1.3% as of December 2025. The article details historical employee counts, showing fluctuations in hiring and growth rates over the past few years. It also provides other workforce metrics like average salary, tenure, and active job postings, and mentions RxSight's business as an ophthalmic medical technology corporation.
Body Composition Analyzers Market Size Accelerating at 11.2%
The Body Composition Analyzers Market is projected to grow substantially, driven by increasing health awareness and integration with digital healthcare. The market size is expected to reach $1.95 billion by 2033, accelerating at an 11.2% CAGR from 2026. Key trends include the integration of AI for enhanced accuracy, a shift towards portable and wireless devices, and significant growth opportunities in telehealth and wearable device integration, particularly in North America and Asia-Pacific.
Top medtech executive moves in 2026
The medtech industry has seen significant leadership changes in 2026, with companies like Hologic, Teleflex, and Grail appointing new CEOs as they navigate investments and product portfolio shifts. Notably, José Almeida joined Hologic, Jason Weidman took the helm at Teleflex, and Grail's CEO Bob Ragusa retired following a clinical trial setback. STAAR Surgical is also actively searching for a permanent CEO after shareholder rejection of a buyout offer led to its previous leader's departure.
Hologic, Inc. (HOLX) Stock Analysis: Exploring the Healthcare Giant’s Strong Position with Limited Upside
Hologic, Inc. (HOLX) is a healthcare company specializing in women’s health diagnostics, imaging, and surgical products, with a robust market capitalization and strong cash flow. Despite its solid standing and stable performance, analysts have a unanimous 'hold' rating, anticipating limited upside potential (around 0.86%). The stock is currently trading near its 52-week high, and investors might consider awaiting clearer growth drivers or a more attractive entry point.
Vanguard owns 16.7M Hologic shares in filing (HOLX) — 7.49% stake disclosed
Vanguard Capital Management has disclosed a 7.49% stake in Hologic Inc. (HOLX), beneficially owning 16,721,923 shares as of March 31, 2026. This position is aggregated across various Vanguard affiliates and funds, with sole voting power over 2,218,009 shares and sole dispositive power over all 16,721,923 shares. The filing, a Schedule 13G, indicates a passive investment intent.
Hologic Stock (US4364401012): Earnings Release Scheduled for Today
Hologic Inc. (NASDAQ: HOLX) is scheduled to release its fiscal Q3 2026 earnings today, April 30, 2026. Investors are keen on updates regarding revenue growth, procedure recovery trends, and margin performance, especially in light of strong U.S. market conditions and resilient consumer spending. The company, which specializes in women's health solutions through diagnostics, imaging, and surgical products, previously projected mid-single-digit revenue growth for fiscal 2026.
Evaluating Innovations in Middle Molecule Clearance
DaVita is exploring innovations in middle molecule clearance, focusing on hemodiafiltration and expanded hemodialysis, to improve patient outcomes in kidney care. These therapies are considered crucial for addressing inflammation, cardiovascular risk, and recovery post-dialysis. The company emphasizes the necessity of validating these treatments within the U.S. context to establish new standards of care.
Conestoga Capital Adds Artivion to Portfolio Amid Market Volatility
Conestoga Capital Advisors added Artivion, Inc. (NYSE:AORT) to its portfolio in Q1 2026, despite a challenging market environment marked by geopolitical tensions and significant volatility. The firm's Small Cap Composite saw a decline of 5.01%, underperforming the Russell 2000 Growth Index. Conestoga remains confident in Artivion's growth prospects, citing its focus on complex aortic repair and new product development.
HPV Testing Market Size Expected to Reach $18.6 Billion at 11.2%
The HPV Testing Market is projected to reach $18.6 billion by 2033, growing at an 11.2% CAGR from 2026, driven by increased cervical cancer screening programs, rising awareness, and advancements in molecular diagnostics. Geopolitical tensions have reshaped supply chains, accelerating manufacturing localization in the US. The report highlights critical growth metrics, emerging investment opportunities, technological advancements like AI, and competitive dynamics among key players such as Roche Diagnostics and Hologic Inc.
Baxter discloses executive pay under new CEO and golden parachute for the last CEO
Baxter International recently disclosed the compensation packages for its new CEO, Andrew Hider, and other executives, including severance for former CEO Joe Almeida. Hider received $29.8 million in 2025, largely composed of stock awards and a sign-on bonus, while Almeida received $7.7 million, which included a $6.9 million lump sum for termination without cause. The company also reported an increased pay ratio, with the CEO earning 445 times more than the median employee.
Blackstone, TPG said to be nearing over $17B deal for Hologic
The article states that Blackstone and TPG are reportedly close to finalizing a deal to acquire Hologic for over $17 billion. Further details on the acquisition are expected soon.
Blackstone, TPG said to be nearing over $17B deal for Hologic
The article reports that Blackstone and TPG are reportedly close to finalizing a deal to acquire Hologic for over $17 billion. Further details about the potential acquisition were not immediately available in the provided content.
Medicinal Microbiology Market Is Going to Boom | Major Giants bioMérieux SA, Hologic, Cepheid
The global Medicinal Microbiology Market is projected to reach USD 5 billion by 2033, growing at a CAGR of 6.2% from its current USD 3.3 billion valuation, driven by increasing infectious disease burdens and technological advancements in diagnostics. Key players include Thermo Fisher Scientific, Roche Diagnostics, and bioMérieux SA. The market is propelled by trends such as molecular diagnostics, automation, and point-of-care testing, with significant opportunities in personalized medicine and emerging markets despite challenges like rapid technological change and competitive pressures.
Blackstone & TPG Complete Hologic Acquisition, Appoint Joe Almeida as CEO
Blackstone and TPG have completed their acquisition of Hologic, Inc., taking the women's health MedTech company private in a deal valued at up to $79 per share. The transaction includes minority investments from ADIA and GIC, with Hologic shareholders receiving cash and a contingent value right. Concurrently, José E. Almeida has been appointed CEO, succeeding Stephen MacMillan, and Hologic's common stock has been delisted from Nasdaq.
[8-K] MASIMO CORP Reports Material Event
MASIMO CORP (MASI) filed an 8-K report detailing a material event related to its pending merger with Danaher Corporation. The report provides supplemental disclosures to its definitive proxy statement, addressing stockholder litigation and demand letters concerning the merger. Masimo maintains that its disclosures comply with applicable law, but has supplemented the proxy to mitigate risks of delay to the merger and to minimize litigation costs, without admitting wrongdoing.
Analysts’ Top Healthcare Picks: Surrozen (SRZN), Establishment Labs Holdings (ESTA)
This article highlights bullish analyst ratings for three healthcare companies: Surrozen (SRZN), Establishment Labs Holdings (ESTA), and Medicus Pharma Ltd (MDCX). TD Cowen initiated coverage on Surrozen with a Buy rating, while reiterating a Buy rating on Establishment Labs Holdings. Roth MKM also started coverage on Medicus Pharma Ltd with a Buy rating, indicating positive sentiment in the sector.
New Evidence Backs Hologic’s AI-Powered Mammography Technology for Detecting Challenging Cancers
New research presented at the Society of Breast Imaging (SBI) Symposium highlights the effectiveness of Hologic’s AI-driven breast cancer detection technologies, particularly for challenging cases like invasive lobular cancer. A study conducted at Massachusetts General Hospital demonstrated that Hologic's Genius AI® Detection solution identified nearly 90% of confirmed invasive lobular cancers, including 43% of those initially missed in routine screenings. This suggests AI can act as a powerful supportive tool for radiologists, though further research is needed on its real-time clinical impact and broader applicability.
Interventional Radiology Market is expected to Hit US$ 47.25 Billion by 2033 | Major Companies - GE Healthcare, Hologic Inc., Shimadzu Corporation, Carestream Health
The global Interventional Radiology Market is projected to reach US$ 47.25 billion by 2033, growing at a CAGR of 5.9% from 2026. This growth is driven by increasing demand for minimally invasive procedures and advancements in imaging technologies. Key market players include GE Healthcare, Hologic Inc., and Shimadzu Corporation, with significant recent developments in AI-powered imaging, hybrid systems, and strategic acquisitions.
PennyMac Mortgage Investment Trust (NYSE: PMT) details 2026 virtual meeting and board votes
PennyMac Mortgage Investment Trust (PMT) has detailed its 2026 Annual Meeting of Shareholders, scheduled for June 16, 2026, where shareholders will vote on key proposals including the election of three Class II trustees, the ratification of Deloitte & Touche LLP as independent auditors, and the advisory approval of executive compensation. The Board unanimously recommends voting "FOR" all proposals and emphasizes its commitment to strong corporate governance, independent oversight, and aligning executive incentives with shareholder interests through various compensation policies. The article also provides detailed financial information, including audit fees and compensation data, and outlines the company's approach to risk management and corporate sustainability.
